OR WAIT 15 SECS
Chitra Sethi, Managing Editor, BioPharm International
ATMI Inc. has established a North American hub for the production, marketing, and development of its single-use technologies for biopharmaceutical and other life sciences applications by expanding its Bloomington, MN manufacturing facility.
ATMI, Inc. has established a North American hub for the production, marketing, and development of its single-use technologies for biopharmaceutical and other life sciences applications by expanding its Bloomington, MN manufacturing facility. The North American site was launched at an official ribbon-cutting ceremony on July 28, 2010.
The added capabilities double ATMI's worldwide capacity for ATMI LifeSciences' Integrity product line of 2-D and 3-D transfer, storage, mixing, and bioreactor vessels, while adding supply chain contingency through a dual-manufacturing capability shared with existing manufacturing plant in Hoegaarden, Belgium.
"Creating a copy-exact of our Belgian facility for change management and supply chain security reasons also helped us to quickly replicate cGMP procedures," said ATMI CEO and President Doug Neugold.
Featuring a 2,500 sq. ft. Class 1000 cleanroom with Class 100 work areas, the additions also include a new demonstration and applications laboratory and a separate product development laboratory. The production area has a dedicated space to perform 100% integrity testing of each fully assembled vessel, including bioburden, weld strength, and particle contamination monitoring.
"Increasing our manufacturing footprint addresses the rapidly increasing demands of the biopharmaceutical marketplace for single-use vessels applications in the field of storage, mixing and bioreactors," said Mario Philips, senior vice president and general manager of ATMI LifeSciences.